FREDERICK, Md., Jan. 04, 2018 -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com makes wearable, drug-free chronic pain therapy medical devices. It is pleased to announce that the UK’s government funded public health service, National Health System (NHS), has approved our application to cover and pay for ActiPatch® Musculoskeletal Pain Therapy. The NHS estimates that almost half of the 50 million UK adults may be living with chronic-pain¹, which is why there are more than 100,000 physician visits every day for musculoskeletal pain alone².
The ActiPatch is a drug-free, wearable medical device that regulates peripheral nerve activity to provide pain relief. The NHS based its decision considering strong clinical evidence and a health economics study, which found that ActiPatch significantly decreased pain and improved quality of life, while reducing overall healthcare costs by 42% (58.5% reduction in physician appointment costs, 35% reduction in prescription medication costs).
“This is a major win for pain sufferers in the UK, since they will now be able to obtain a prescription for ActiPatch, the cost of which will be covered by the government,” stated Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics. “We commend this move by the NHS, as this will open up the doors for reimbursement in the US and other managed care markets. This will likely have a tremendous impact on our sales and marketability of the product in the UK and elsewhere,” said Keith Nalepka, VP of Sales & Marketing at BioElectronics.
With the addition of ActiPatch to list of approved treatments, chronic pain sufferers now have access to paid safe, drug-free chronic pain relief. The ActiPatch will be listed for payment coverage in April.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: For more information, please visit www.bielcorp.com.
References
1 NHS, "NHS Choices," January 2018. [Online]. Available: https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pai....
2 Arthritis Research UK, "Muscloskeletal Matters," Keele University, 2009.
Contact: Paul Knopick 940.262.3584 [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Washington Post Publisher Will Lewis Steps Down After Layoffs
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 



